SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

J-L Boulay*,1, G Mild1, A Lowy2, J Reuter1, M Lagrange1,5, L Terracciano3, U Laffer3, R Herrmann4 and C Rochlitz4

1Department of Research, University Hospital, CH-4031 Basel, Switzerland; 2The Swiss Group for Clinical Cancer Research (SAKK), CH-3008 Bern, Switzerland; 3Department of Pathology, University Hospital, CH-4031 Basel, Switzerland; 4Department of Oncology, University Hospital, CH-4031 Basel, Switzerland

The gene for the transducer of transforming growth factor-beta/bone morphogenetic protein signalling SMAD4, a potential suppressor of colorectal carcinogenesis, is located at the chromosomal region 18q21. In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy. Patients with normal SMAD4 diploidy turned out to have a three-fold higher benefit of 5-fluorouracil-based adjuvant chemotherapy with a border line significance (overall survival: 3.23, P=0.056; disease-free survival: 2.89, P=0.045). These data are consistent with the previous observation that patients whose cancer had retention of the 18q21 region had a significantly higher benefit from 5-fluorouracil-based therapy. Moreover, these results may provide a refinement at the gene level of the clinical relevance of 18q21 deletion, thereby suggesting SMAD4 as a predictive marker in colorectal cancer. This data also indicate that integrity of this component of the transforming growth factor-beta/bone morphogenetic protein signalling pathway may be a critical factor for benefit of chemotherapy in patients with colorectal cancer.

Keywords: colorectal cancer; TGFβ; signalling; SMAD; predictive marker

Deletion of the chromosomal region 18q21 is the most frequent cytogenetic alteration observed in colorectal cancer (CRC), suggesting the location of a tumour suppressor locus in this region (Vogelstein et al., 1988; Mitelman et al., 1997). Searches for such candidate genes have led to the identification of a gene designated as Deleted in Pancreatic Cancer locus 4 (DPC4) (Hahn et al., 1996; Thiagalingam et al., 1996). Through its homology with the C. elegans Small (Sma) proteins (Savage et al., 1996) and with the Drosophila protein Mothers against dpp (Mad), initially identified for its genetic interaction with the gene for the BMP-like peptide Decapentaplegic (dpp) (Raftery et al., 1995), DPC4 has been renamed SMAD4 as a merger of Sma and Mad (Derinck et al., 1996).

SMADs form a family of structurally related proteins initially identified for their role in embryonic development of Drosophila (Raftery et al., 1995) and of C. elegans (Savage et al., 1996). Proteins of the SMAD family can be divided into three distinct subtypes that correlate with their respective functions in transforming growth factor beta (TGFβ)/bone morphogenetic protein (BMP) signalling (Kretschmar and Massagué, 1999; Newfeld et al., 1999), as depicted in Figure 1: (i) receptor-activated (ra)-SMADs are serine-phosphorylated upon binding of the cytokine to its cognate receptor. SMAD2 and SMAD3 are specifically activated by TGFβ-like cytokines, whereas SMAD1, SMAD5 and SMAD8 are exclusively phosphorylated by BMPs; (ii) a co-SMAD, SMAD4 heteropolymerises with activated ra-SMADs. This complex migrates to the nucleus where it associates with tissue specific transcription factors. SMAD4 is the only co-SMAD protein known in mammalians, and therefore is a common signalling mediator to all TGFβ/BMPs; and (iii) among the immediate target genes for SMAD transcription complexes are the genes for anti-SMADs. Thus, the anti-SMADs SMAD6 and SMAD7 prevent activation of ra-SMADs (SMAD1/5/8 and SMAD2/3, respectively), therefore providing a transient cytokine response through a negative feedback loop. Interestingly, SMAD2 (Eppert et al., 1996) and SMAD7 (Nakao et al., 1997) genes have also been assigned to the 18q21 region (Eppert et al., 1996; Röijer et al., 1998), where the SMAD7 gene maps between SMAD2 and SMAD4 genes (Boulay et al., 2001) within four megabases (Venter et al., 2001). Thus, this region encodes the three classes of TGFβ mediators specifically required for the signalling of TGFβ-like cytokines, and one, SMAD4, for both TGFβ and BMP families.

Genetic evidence for the involvement of TGFβ pathway in colon tumour suppression was given by Markowitz et al (1995), who observed frequent frameshift mutations within the TGFβ-receptor II coding sequence in CRC, as a result of microsatellite instability. This observation has been later confirmed in a larger population, where most tumors with microsatellite instability carry this gene mutation (Watanabe et al., 2001). On the other hand, TGFβ has been shown to be a potent cell growth inhibitor (Roberts and Sporn, 1993), and apoptosis inducer on prostatic epithelial cell lines (Hsing et al., 1996), whereas most squamous carcinoma lines are refractory to this function (Reiss et al., 1993; Blobè et al., 2000). Thus, the frequent deletion of the chromosomal region 18q21 in colorectal tumours together with the physiologic functions of TGFβ strongly suggested a role for SMAD4 in the suppression of colorectal carcinogenesis.
For these reasons, we wished to study the influence of the SMAD4 gene on the clinical outcome of patients with CRC, including on benefit of 5FU-based chemotherapy. Indeed, an interaction between markers and treatment responsiveness or lack thereof has led to a separation of these factors into prognostic (independent of treatment) and predictive (interactive with treatment) categories. To do so, we took advantage of archived colorectal tumour biopsies collected in a previous Swiss Association for Clinical Cancer Research (SAKK) study of 5FU-based perioperative adjuvant therapy (SAKK, 1995). Through a strategy based on quantitative real time PCR (Boulay et al, 1999, 2001), we performed genetic analyses of corresponding DNAs by copy dosage of the SMAD4 gene. In order to study on one hand the prognostic value of genotype, and on the other hand its predictive effect on the efficacy of 5FU-based therapy among patients with CRC, we undertook multivariate statistical analysis of SMAD4 gene copy status on survival.

MATERIALS AND METHODS

Patients

Patients from whom biopsies were isolated, were part of a previous randomised study of the Swiss Association for Clinical Cancer Research (SAKK) study 40/81 (SAKK, 1995). In that study, 533 patients with colorectal cancer about to undergo curative resection were randomly assigned no adjuvant treatment (control group) or an immediate postoperative infusion with 5FU (500 mg m\(^{-2}\)) for 7 days, with one single dose of mitomycin (10 mg m\(^{-2}\)) on day 1. As a result, patients appeared to significantly benefit from this therapy such that overall survival increased from 55 to 66 months (hazard ratio: 0.74; 95% confidence interval: 0.57 – 0.97; P=0.026), and disease-free survival, from 48 to 57 months (hazard ratio: 0.79; 95% confidence interval: 0.62 – 1.00; P=0.051). The relationship between genotypes and clinical outcome was assessed in a subset of 202 patients with genetic data for which we also had clinical and survival data. As shown in Table 1, the subgroup for which genetic and clinical data are available, is closely representative of the patients treated in the SAKK study 40/81 (SAKK, 1995). Our study comprises 164 out of the 233 individuals described in our previous report (Boulay et al, 2001).

Gene copy status scoring

Genomic samples were tested for gene dosage using the TaqMan\textsuperscript{R} system on an ABI Prism\textsuperscript{R} 7700 sequence detector (PE Applied Biosystems, Foster, USA). All reactions were made in triplicate. For each individual, the Ct value (calculated by the built-in software) obtained for the gene 36B4 (Masiakowski et al, 1982) on normal tissue was subtracted from that of tumour tissue thus defining ΔCt36B4. A similar calculation was made for the SMAD4 gene (ΔCtSMAD4). Gene copy status is indicated by the ΔCt value (ΔCt36B4 – ΔCtSMAD4) as following: ΔCt ≤ –0.45: no deletion; ΔCt < –0.55: hemizygous. Primers: SMAD4, gca gac aag tgg gaa ggt gta atc c and cca ttc tat cat caa cgg gta caa. Probes: SMAD4, tgt tgt gtt ccc tat ggc tgt tta cta tcc a; 36B4: tct cca cag aca agg cca gga tgc g.

Statistical analysis

Cox proportional hazard modelling was undertaken to assess the impact of genotype on overall survival and on disease-free survival after controlling for possible confounding. All analyses were performed using S Plus. The relationship between genotypes and survival/disease-free survival was assessed in a subset of 202 patients with genetic data for whom we also had clinical and survival data.

RESULTS

We aimed to test whether the deletion of the SMAD4 gene would have a significant influence on the outcome of patients with CRC. Within the individual tumours in this statistical analysis, the frequency of SMAD4 gene deletion was 67% (135 out of 202). This deletion frequency was similar to that previously reported (Boulay et al, 1999, 2001).
et al., 2001). For each individual, the associations between gene copy dosage and clinical data was investigated in multivariate statistical analyses that included age, sex, stage, tumour location, grade, nodal status and chemotherapy as covariates. Hazard ratios (HR) for death and relapse associated with SMAD4 gene deletion were close to one (1.22 and 1.16, respectively) with non-significant P values (0.43 and 0.56, respectively, Table 2, top). Thus we concluded that deletion of SMAD4 gene has no significant influence on the outcome of patients with CRC.

The original clinical study from which tumour samples were derived had shown the benefit of 5FU-based perioperative adjuvant chemotherapy in colorectal cancer (SAKK, 1995). Thus, a similar multivariate statistical analysis was performed to evaluate the deletion of the SMAD4 gene as a potential marker for a predictive effect on 5FU treatment. Regarding disease-free survival, after controlling for confounding in the multivariate models, the HR associated with 5FU treatment among patients with normal diploidy for SMAD4 was 0.32, whereas the HR associated with 5FU treatment in patients with SMAD4 deletion was 2.89 times as large (Table 2, bottom). The difference between these two HRs (i.e. the statistical interaction between gene deletion and the effect of 5FU chemotherapy) was of borderline statistical significance (P=0.045). A similar result was found for overall survival, the HR associated with 5FU treatment being 0.25 among patients with normal SMAD4 genotype and 3.23 times as great among patients with SMAD4 deletion (Table 2, bottom; Figure 2). As with disease-free survival, the difference was of borderline statistical significance (P=0.056). This suggests SMAD4 as a predictive marker for 5FU/mitomycin adjuvant chemotherapy.

**DISCUSSION**

We established that among the patients with colorectal cancer involved in this study, SMAD4 was deleted in 67% of cases. These results, obtained by gene copy dosage, are consistent with those

### Table 2

| Association of SMAD4 status with patient outcome | Hazard ratio | 95% CI      | P-value |
|-------------------------------------------------|-------------|-------------|---------|
| **Prognostic effect of SMAD4 gene deletion**     |             |             |         |
| Overall survival                                | 1.22        | 0.75 – 1.96 | 0.43    |
| Disease-free survival                           | 1.16        | 0.74 – 1.81 | 0.51    |
| **Predictive effect of SMAD4 gene deletion of 5FU adjuvant therapy** |             |             |         |
| Overall survival                                | 3.23        | 0.97 – 10.8 | 0.056   |
| Treated group                                   | 2.85        | 0.98 – 8.33 | 0.055   |
| Untreated group                                 | 0.87        | 0.49 – 1.54 | 0.64    |
| Disease-free survival                           | 2.89        | 1.02 – 8.12 | 0.045   |
| Treated group                                   | 2.31        | 0.95 – 5.62 | 0.066   |
| Untreated group                                 | 0.81        | 0.47 – 1.40 | 0.45    |

Figure 2 Kaplan–Meier plotting of survival in response to 5FU therapy in patients (n=202) with SMAD4 deletion (top) and with no loss of SMAD4 (bottom). Overall survival (left): HR=3.23, 95% CI=0.97 – 10.8, P=0.056. Disease-free survival (right): HR=2.89, 95% CI=1.02 – 8.12, P=0.045.
deduced from earlier cytogenetic (Vogelstein et al., 1988; Mitelman et al., 1997) and loss of heterozygosity (LOH) studies on the 18q21 region (Laurent-Puig et al., 1992; Jen et al., 1994; Martínez-López et al., 1998; Jernwall et al., 1999; Watanabe et al., 2001). However, these LOH studies are frequently based on microsatellite markers that span several centiMorgans (cM), and therefore several megabases (Mb). In contrast to that approach, our strategy allows for a more refined analysis by targeting an individual gene rather than a wide chromosomal region that contains a number of important genes. Thus, it is likely that an analysis at the single gene level will provide a more accurate image of eventual clinical implications of genetic alterations.

We observed that colorectal cancer patients with normal SMAD4 gene copy status had a three-fold higher benefit of 5FU-based therapy than those with SMAD4 deletion. This result is consistent with the previous observation by Watanabe et al. (2001), that patients with retention of 18q21 alleles had a benefit of 5FU-based chemotherapy of the same order as was found in this study. Moreover, refinement of deletion studies from the chromosomal band level to the gene level may provide a clue to possible mechanisms through which 18q21 deletion influences the outcome of patients with CRC. Therefore, our results reinforce the hypothesis that TGFβ and its signalling components have a role in tumour suppression. This result also suggests the definition of SMAD4 as a predictive marker for benefit of 5FU-based chemotherapy in patients with colorectal cancer. Finally, these findings suggest a mode of action of this cytostatic compound that is SMAD4-dependent. Thus, the integrity of this component of the TGFβ/BMP pathway is not only required for cytokine signalling, but may also be an important factor for 5FU-mediated apoptosis. In addition to the requirement of functional apoptotic pathways such as CD95/Fas (Houghton et al., 1997), bax (Rampino et al., 1997) and p53 (Vogelstein et al., 2000) for drug sensitivity in colorectal tumour cells, this suggests that integrity of the TGFβ pathway may be an additional condition for efficiency of 5FU treatment. Thus, our results provide an additional clue to the genetic basis of drug resistance in cancer.

ACKNOWLEDGEMENTS

Supported by the Swiss Cancer League, the Krebsliga beider Basel, the Sander Stiftung and by the Novartis (formerly Ciba-Geigy) Foundation.

REFERENCES

Bloge GC, Schieman WP, Lodish HF (2000) Role of the transforming growth factor β in human disease. N Engl J Med 342: 1350 – 1358
Boulay JL, Reuter J, Ritschard B, Terracciano L, Herrmann R, Rochlitz C (1999) Gene dosage by quantitative real-time PCR. Biotechniques 27: 228 – 232
Boulay JL, Mild G, Reuter J, Lagrange M, Terracciano L, Lowy A, Laffer U, Orth B, Metzger U, Stamm B, Martinoli S, Herrmann R, Rochlitz C (2001) Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. Genes Chrom Cancer 31: 240 – 247
Derick R, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massague J, Melton DA, Harland RM, Heldin CH, Kern SE, Massague J, Melton DA, Mlodzik M, Padgett RW, Roberts AB, Smith J, Thomasen GH, Vogelstein B, Wang XF (1996) Nomenclature: vertebrate mediators of TGFβ family signals. Cell 87: 173
Eppert K, Scherer SW, Ozelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Derinck R, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massague J, Melton DA, Mlodzik M, Padgett RW, Roberts AB, Sporn MB (1993) The transforming growth factor-betas. In: Robins HR, Grell CL, editors. Cell biology of growth factor action. New York: Plenum Press. p 1180 – 1187
Hahn SA, Schutte M, Shamsul Hoque ATM, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumour suppressor gene at human chromosome 18q21.1. Science 271: 350 – 353
Houghton JA, Harwood FG, Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via Fas signalling. Proc Natl Acad Sci USA 94: 8144 – 8149
Hsing AY, Kadomatsu K, Bonham MJ, Danielpour D (1996) Regulation of apoptosis induced transforming growth factor-beta in nonmitogenic and tumorigenic rat prostatic epithelial cell lines. Cancer Res 56: 5146 – 5149
Jen J, Kim H, Piantadosi S, Liu AF, Levitt RC, Sistonen P, Kinzler KW, Vogelstein B, Wang XF (1996) Nomenclature: vertebrate mediators of TGFβ family signals. Cell 87: 543 – 552
Laurent-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselain B, Melot T, Viallon V, Poirier J-L, Boulay J-L, et al (1998) Allelic loss on chromosome 18q in colorectal cancer. Br J Cancer 78: 903 – 908
Kretschmar M,Massague J (1999) SMADs: mediators and regulators of TGF-β signalling. Curr Opin Genet Dev 8: 103 – 111
Laurent-Puig P, Olschwang S, Delattre O, Rempikos Y, Asselain B, Melot T ValidireP, Mulieris M, Giordet J, Salmon RJ (1992) Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136 – 1141
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KB, Vogelstein B, Brattain M, Williams JKV (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268: 1336 – 1338

© 2002 Cancer Research UK

British Journal of Cancer (2002) 87(6), 630 – 634

Spanish randomised trial of a single course of adjuvant intraportal chemotherapy for colorectal cancer. The Lancet 345: 349 – 353
Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, Willson JKV, Markowitz S, Hamilton SR, Kern SE, Kinzler KW, Vogelstein B (1996) Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. *Nature Genet* 13: 343 – 346

Venter C *et al* (2001) The sequence of the human genome. *Science* 291: 1304 – 1345

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumour development. *N Engl J Med* 319: 525 – 532

Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson III AB, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. *N Engl J Med* 344: 1196 – 1206

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. *Nature* 408: 307 – 310